Moneycontrol PRO
HomeNewsProduct launch

Product Launch

Jump to
  • ITC to launch health and nutrition brand 'Right Shift' in next 10 days: CMD Sanjiv Puri

    "The brand is expected to launch in a week or next 10 days and will offer targeted dense nutrition for strength and energy building," announced the chairman and managing director Sanjiv Puri of ITC at a media interaction post-annual general meeting on July 26.

  • Lupin gets approval from US FDA for Ganirelix Acetate injection

    The product will be manufactured at Lupin’s Nagpur facility in India.

  • Dr Reddy’s rolls out wearable migraine management device in India

    Nerivio is a drug-free wearable and intended for acute and prophylactic (preventive) migraine in patients aged 12 years and above

  • Lupin and Amman Pharma sign licensing agreement for Ranibizumab biosimilar

    Ranibizumab is used in the treatment of various age related eye conditions.

  • Apple Spring Loaded event: New iPad pro, iMac & AirTags unveiled

    Apple's Spring event was about the iMac and a few upgrades. The iMac 2021 was the biggest product launch of the Apple Spring Event. Watch the video to know more

  • Dr Reddy’s revs up product launches after costs recalibration, execution key

    New product launch momentum is gathering pace at Dr Reddy’s Laboratories with the company targeting to introduce 30 drugs in the US this fiscal. While the company is also working on COVID-19 medicines, success is contingent on positive research outcomes

  • Nestle to enter organic food segment in India with Nestle Ceregrow

    Nestlé India announced a growth of over 10 percent for its January-March quarter results on May 14.

  • Hero MotoCorp unveils 15 new products

    The offerings include a refreshed version of its high-end bike Karizma. This is Hero's first commercial production model in which US-based partner Erik Buell Racing (EBR) has played a major development role since their tie-up.

  • Teva will get part of profit from Lipitor sale by Ranbaxy

    Industry sources tell PharmAsia News that Ranbaxy forged the Teva Lipitor deal as a back-up plan to try and ensure an on-time launch.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347